Canopy Growth Launches Canadian-Bred 7ACRES Cannabis Brand in Australia

Expansion Brings Two Popular High-THC Strains to Australian Medical Patients

Smiths Falls-Based Canopy Growth Corp. Expands Its Global Footprint

Canopy Growth Corp., a global leader in cannabis innovation and production, has officially launched its premium Canadian-grown 7ACRES cannabis brand in Australia. This strategic move complements its existing Tweed flower and Spectrum Therapeutics oil offerings, expanding the company’s medical cannabis portfolio with two sought-after sativa strains: Ultra Jack and Jack Frost.

The announcement was made on August 5, 2025, and marks a significant step in Canopy Growth’s global expansion strategy, particularly in the medical cannabis sector.

Two High-THC Sativa Strains Set to Serve Australia’s Medical Market

7ACRES introduces Australian patients to two popular strains that have already gained a strong following in the Canadian market.

• Ultra Jack, a cross between Ultra Sour and Jack Haze, is widely known for its energizing effects and is one of the top-performing strains in both medical and adult-use markets in Canada. 
• Jack Frost, a hybrid of White Widow and Cold Creek Kush, brings balanced cerebral effects and flavor-forward genetics, enriching the therapeutic options available to Australian medical cannabis patients. 

Both strains are being made available in 10-gram flower formats, tailored for patients requiring high-potency, terpene-rich products to support various medical conditions.

A More Diverse Portfolio for Australian Prescribers and Patients

“Adding 7ACRES to our Australian portfolio helps ensure patients and prescribers have access to a diverse range of high-quality flower options,” said Andrew Bevan, Senior Vice President of Global Medical at Canopy Growth. He emphasized the importance of reliable supply chains and product consistency in delivering premium medical cannabis experiences.

Bevan highlighted that recent enhancements in the company’s global logistics and production systems allow Canopy to meet rising international demand with a dependable and standardized product pipeline.

Strategic Global Growth Focused on Medical Markets

According to Canopy Growth CEO Luc Mongeau, the company views international medical markets as one of its most promising commercial opportunities. “Our ability to scale high-quality production in Canada and reliably supply international markets remains a key strength as we expand our global medical platform,” said Mongeau.

This expansion into Australia reflects the company’s continued investment in medical research, global infrastructure, and patient-centered solutions.

Building on an Existing Australian Presence

The 7ACRES launch builds on Canopy Growth’s well-established presence in Australia. The company already markets Tweed-branded flower products and Spectrum Therapeutics cannabis oils, which are offered in color-coded formulations—Red, Yellow, White, and Blue—to guide dosage and cannabinoid content for medical use.

With the addition of 7ACRES flower, Canopy Growth now offers a more comprehensive and differentiated range of products to serve the diverse needs of the Australian medical community.

Meeting International Standards for Medical Cannabis

Canopy Growth has consistently positioned itself as a pioneer in quality, compliance, and product innovation in cannabis. The 7ACRES flower is cultivated under Good Production Practices (GPP) in Canada, and all export-bound products meet stringent Australian regulatory standards for medical cannabis.

This ensures prescribers and patients receive pharmaceutical-grade cannabis that’s not only potent but also consistently manufactured with verified cannabinoid profiles and tested for contaminants.

Strengthening Supply Chains to Meet Growing Global Demand

Canopy Growth’s ability to export product from Canada into markets like Australia has been bolstered by improvements to its international logistics, compliance systems, and tracking infrastructure.

With streamlined processes, Canopy is now better equipped to meet rising demand in regulated medical markets, especially in regions that require long-term consistency and traceability, such as Australia and the European Union.

A Signal to Other Global Markets and Investors

This expansion also sends a broader signal to the international cannabis industry: Canadian-grown cannabis brands are successfully scaling globally. As more countries adopt or reform medical cannabis laws, companies like Canopy Growth are poised to provide products that meet medical standards while supporting local market development.

It also reinforces investor confidence in the potential for growth beyond North America, especially in regulated medical markets with high entry barriers and complex compliance needs.

The Future of Medical Cannabis in Australia and Beyond

Canopy Growth’s latest move reaffirms its ambition to lead the global cannabis industry—not only by volume, but by innovation, compliance, and patient care. With a strong foundation now laid in Australia, the company may soon explore similar opportunities in other Asia-Pacific and European markets where regulatory frameworks are evolving.

As Australia’s medical cannabis patient base continues to grow, the addition of 7ACRES could become a significant value driver for Canopy and a game-changer for patients seeking more diverse, high-quality cannabis treatment options.